Hsbc Holdings PLC Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Hsbc Holdings PLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) by 25.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,199 shares of the biopharmaceutical company’s stock after buying an additional 9,014 shares during the quarter. Hsbc Holdings PLC’s holdings in Alnylam Pharmaceuticals were worth $8,470,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of ALNY. ANTIPODES PARTNERS Ltd boosted its stake in shares of Alnylam Pharmaceuticals by 69.1% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock valued at $36,203,000 after purchasing an additional 77,307 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in shares of Alnylam Pharmaceuticals by 155.7% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the period. Westpac Banking Corp boosted its stake in shares of Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 566 shares during the period. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter. Vanguard Group Inc. now owns 11,656,831 shares of the biopharmaceutical company’s stock valued at $2,064,425,000 after purchasing an additional 30,608 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Alnylam Pharmaceuticals by 630.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,160 shares of the biopharmaceutical company’s stock valued at $5,007,000 after purchasing an additional 22,580 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $148.43 on Monday. The stock has a market capitalization of $18.78 billion, a P/E ratio of -55.38 and a beta of 0.41. The company’s fifty day moving average is $149.50 and its two-hundred day moving average is $163.40. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.40) earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on ALNY shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Citigroup decreased their price target on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research note on Friday, February 16th. Needham & Company LLC reiterated a “buy” rating and issued a $200.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 2nd. Chardan Capital reissued a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. Finally, Wells Fargo & Company cut their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $216.19.

Check Out Our Latest Stock Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Profile

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Recommended Stories

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.